Clinical Trial Update: Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 68GaNOTA-Anti-MMR-VHH2 imaging agent across multiple indications including solid malignancies of the head and neck, various ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis of Artery
• Cancer
• Cardiac Sarcoidosis
• Carotid Stenosis
• Hlh
• Hodgkin Lymphoma Adult
• Non-hodgkin Lymphoma
• Sarcoidosis
• Solid Malignancy Located in the Head and Neck

Drugs mentioned

• 68GaNOTA-Anti-MMR-VHH2 (Anti-MMR-VHH2)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Solid Malignancy Located in the Head and Neck, Cancer | Phase 2 | Status: UNKNOWN